PBM (Psyence Biomedical) Total Assets: $17.57 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBM Psyence Biomedical Ltd PBM
14 GF Score
Price $5.40
! 4 Warning Signs
View Full Analysis

What is Psyence Biomedical Total Assets?

Psyence Biomedical PBM +9.64% 14 Total Assets is $17.57 Mil as of Mar. 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Psyence Biomedical's Total Assets for the quarter that ended in Mar. 2026 was $17.57 Mil.

During the past 12 months, Psyence Biomedical's average Total Assets Growth Rate was 757.10% per year. During the past 3 years, the average Total Assets Growth Rate was 240.70% per year. During the past 5 years, the average Total Assets Growth Rate was 133.00% per year.

During the past 6 years, Psyence Biomedical's highest 3-Year average Total Assets Growth Rate was 240.70%. The lowest was 39.20%. And the median was 144.30%.

Total Assets is connected with ROA %. Psyence Biomedical's annualized ROA % for the quarter that ended in Mar. 2026 was -65.09%. Total Assets is also linked to Revenue through Asset Turnover. Psyence Biomedical's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Psyence Biomedical  (NAS:PBM) Total Assets Explanation

Total Assets is connected with ROA %.

Psyence Biomedical's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-9.886/( (12.81+17.567)/ 2 )
=-9.886/15.1885
=-65.09 %

Note: The Net Income data used here is two times the semi-annual (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Psyence Biomedical's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (12.81+17.567)/ 2 )
=0/15.1885
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Psyence Biomedical Total Assets Related Terms

Psyence Biomedical Total Assets Historical Data

* Premium members only.

The historical data trend for Psyence Biomedical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psyence Biomedical Total Assets Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Assets
Get a 7-Day Free Trial 1.83 1.59 1.13 7.32 17.57

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 2.25 7.32 12.81 17.57
PBM
14GF Score
Psyence Biomedical Ltd PBM
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Psyence Biomedical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Psyence Biomedical's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (A: Mar. 2026 )+Total Liabilities (A: Mar. 2026 )
=16.944+0.623
=17.57

Psyence Biomedical's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=16.944+0.623
=17.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $17.57 Mil mean?
Psyence Biomedical (PBM) has a Total Assets of $17.57 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Psyence Biomedical and its competitors.
Is Psyence Biomedical's Total Assets too high?
Psyence Biomedical's current Total Assets is $17.57 Mil. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's Total Assets compare to NRSN and PLUR?
Psyence Biomedical's Total Assets of $17.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Psyence Biomedical and its competitors. Psyence Biomedical's current Total Assets is $17.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current Total Assets of $17.57 Mil. The current Total Assets is $17.57 Mil. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current Total Assets is $17.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Psyence Biomedical Business Description

Address 121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score

Get the complete analysis for PBM

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.40
Price